JNJ-95566692 enters phase 1, with Qilu neck and neck.
ApexOnco Front Page
Recent articles
Majestec-9, in post-Darzalex multiple myeloma, is the latest success.
A pivotal trial will test the KRAS G12D degrader setidegrasib plus chemo in first-line PDAC.
Data from the Ilustro trial support the initiation of the phase 3 Lucerna study.
The group’s on/off KRAS G12C inhibitor looks good, though patient numbers are small.
Four months after yielding first-in-human data INCA33890 enters phase 3.
But Tevimbra’s role looks shaky as adverse events loom.
JP Morgan approaches.
